[CTLA4-Ig (abatacept)].

Abstract

Although tumor necrosis factor (TNF) antagonists have dramatically improved the outcome of patients with rheumatoid arthritis (RA), some of the patients do not respond or cannot tolerate these drugs. Abatacept is a recombinant fusion protein containing components of IgG and cytotoxic T-lymphocyte-associated antigen-4 that inhibit costimulatory signal from antigen presenting cells and prevent activation of T cells. Several clinical trials have demonstrated the excellent efficacy and safety of abatacept in patients with RA who are resistant to methotrexate or TNF antagonists. Abatacept improved clinical signs and symptoms and quality of life of patients with RA and also retarded their radiological progression of structural damage of affected joints. The safety concerns, especially for infections and malignancies, are raised and should be strictly monitored in clinical trials and future clinical practice in Japan as well as in Western countries.

• Authors: Masayoshi Harigai
• Journal: Nihon rinsho. Japanese journal of clinical medicine (Nihon Rinsho) Vol. 65 Issue 7 Pg. 1231-7 (Jul 2007) ISSN: 0047-1852 [Print] Japan
• PMID: 17642237 (Publication Type: English Abstract, Journal Article, Review)

Chemical References

• Antirheumatic Agents
• Immunoconjugates
• Abatacept

Topics

• Abatacept
• Antigen-Presenting Cells (immunology)
• Antirheumatic Agents (adverse effects, chemistry, pharmacology, therapeutic use)
• Arthritis, Rheumatoid (drug therapy, immunology)
• Clinical Trials as Topic
• Drug-Related Side Effects and Adverse Reactions
• Humans
• Immunoconjugates (adverse effects, chemistry, pharmacology, therapeutic use)
• Lymphocyte Activation
• T-Lymphocytes (immunology)
• Treatment Outcome